Additive effect of dornase alfa and Nacystelyn on transportability and viscoelasticity of cystic fibrosis sputum

Canadian Respiratory Journal

Volumn 9, Issue 6, 2002, Pages 401-406

  Sun, Feng ^a   Tai, Shusheng ^a   Lim, Thomas ^a   Baumann, Ulrich ^b   King, Malcolm ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cystic fibrosis; Mucociliary transport; Mucolytics; Sputum viscoelasticity

Indexed keywords

AZITHROMYCIN; DNA; DORNASE ALFA; MUCIN; MUCOLYTIC AGENT; NACYSTELYN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANIMAL TISSUE; ARTICLE; CHEMICAL BOND; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; DRUG SOLUTION; FROG; HUMAN; IN VITRO STUDY; INCUBATION TIME; LABORATORY; LUNG CLEARANCE; MUCOCILIARY TRANSPORT; NONHUMAN; PALATE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SAMPLE; SCHOOL CHILD; SPUTUM EXAMINATION; VISCOELASTICITY;

EID: 0036879638     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2002/508942     Document Type: Article

References (21)

1. Daviskas E, Anderson SD. Interventions that increase mucociliary clearance in asthmatic and healthy subjects. In: Baum GL, Priel Z, Roth Y, et al, eds. Cilia, Mucus, and Mucociliary Interactions. New York: Marcel Dekker, 1998:295-305.
2. Shak S, Capon DJ, Hellmiss R, et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990;87:9188-92.
3. Lethem MI, James SL, Marriott C, et al. The origin of DNA associated with mucus glycoprotein in cystic fibrosis sputum. Eur Respir J 1990;3:19-23.
4. Dasgupta B, King M. Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with Nacystelyn and rhDNase. Pediatr Pulmonol 1996;22:161-6.
5. Tai S, Kai H, Isohama Y, et al. The effect of deoxyribonuclease I on tracheal mucociliary transport and airway secretion in anesthetized quails. Pharmacol Rev Commun 1999;10:257-64.
6. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbation of respiratory symptoms and on pulmonary function in cystic fibrosis. N Engl J Med 1994;331:637-48.
7. King M, Rubin BK. Mucus controlling agents: Past and present. Respir Care Clin North Am 1999;5:575-94.
8. Tomkiewicz RP, App EM, Coffiner M, et al. Mucolytic treatment with N-acetylcysteine L-lysinate metered dose inhaler in dogs: Airway epithelial function changes. Eur Respir J 1994;7:81-7.
9. Sheffner AL. The reduction in vitro in viscosity of mucoprotein solutions by a new mucolytic agent, N-acetylcysteine. Ann NY Acad Sci 1963;106:298-310.
10. App EM, Baran D, Dab I, et al. Dose-finding and 24-hour monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis. Eur Respir J 2002; 19:294-302.
11. Sun F, Tai S, App EM, et al. Mucolytic sensitivity to rhDNase and N-acetylcysteine in cystic fibrosis patient sputum. Am J Respir Crit Care Med 2000;161:A855. (Abst)
12. King M. Magnetic microrheometer. In: Braga PC, Allegra L, eds. Methods in Bronchial Mucology. New York: Raven Press, 1988:73-83.
13. Rubin BK, Ramirez, King M. Mucus-depleted frog as a model for the study of mucociliary clearance. J Appl Physiol 1990;69:424-9.
14. Zahm JM, Girod de Bentzmann S, Deneuville E, et al. Dose-dependent in vitro effect of recombinant human DNase on the transport properties of cystic fibrosis respiratory mucus. Eur Respir J 1995;8:381-6.
15. Ventresca GP, Cicchette V, Ferrari V. Acetylcysteine. In: Braga PC, Allegra L, eds. Drugs in Bronchial Mucology. New York: Raven Press, 1989: 77-102.
16. Marriott C, Ingham S, Coffiner M, et al. Determination of the model of action of a novel mucolytic agent Nacystelyn. Eur Respir J 1993;6:438S. (Abst)
17. App EM, Tomkiewicz RP, Hochstrasser K, et al. New MDI mucolytic Nacystelyn compared with N-acetylcysteine and other reducing agents in human sputum rheology and bronchial secretion inhibitor activity in vitro. Eur Respir J. 1992;5:129S. (Abst)
18. King M. Mucus, mucociliary clearance and coughing. In: Bates DV. Respiratory Function in Disease. Philadelphia: WB Saunders, 1989:69-78.
19. Sinicropi DV, Williams M, Prince WS, et al. Sputum pharmacodynamics and pharmocokinetics of recombinant human Dnase 1 in cystic fibrosis. Am J Respir Crit Care Med 1994;149:A671. (Abst)
20. Shah PL, Ingham S, Marriott C, et al. The in vitro effects of two novel drugs on the rheology of cystic fibrosis and bronchiectasis sputum. Eur Respir J 1994;7:12S. (Abst)
21. Dasgupta B. New methods for mucolysis in cystic fibrosis. MSc thesis. Edmonton: University of Alberta, 1995.